Ainos Current CFO Celia Wu Announces Her Retirement And Transition To Consulting Role

Current CFO Celia Wu announces her retirement and transition to consulting role Sung brings nearly two decades of public company audit and compliance experience with major international accounting firms SAN DIEGO, CA /

Current CFO Celia Wu announces her retirement and transition to consulting role

Sung brings nearly two decades of public company audit and compliance experience with major international accounting firms

SAN DIEGO, CA / ACCESSWIRE / May 17, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW))))) (“Ainos”, or the “Company”), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced the appointment of Ms. Meng-Lin (Amanda) Sung to the position of Chief Financial Officer, effective May 17, 2023. Ms. Sung will succeed Ms. Hui-Lan (Celia) Wu, who is retiring from her position as Chief Financial Officer and will transition into an external consulting role.

Chun-Hsien Tsai, Ainos’ Chairman of the Board, President, and Chief Executive Officer, commented, “I am thrilled to welcome Ms. Sung to our company in the role of Chief Financial Officer. Ms. Sung’s wealth of accounting experience, extensive familiarity with auditing healthcare and life science companies, and unwavering professionalism make her an invaluable addition to our management team. On behalf of everyone at Ainos, I also want to thank Ms. Wu for her hard work and dedication during a truly transformative period of our company’s history. We are incredibly grateful for her contributions to our team, and look forward to continuing working with her in her new capacity as a consultant.”

Ms. Sung comes to Ainos after serving as Vice President of Finance at Sercomm Corporation since late 2021. Prior to joining Sercomm, Ms. Sung held roles at three of the big four accounting firms – PricewaterhouseCoopers, Ernst & Young, and Deloitte – conducting audits and advising public companies on U.S. GAAP/IFRS and SEC reporting and listing regulations. Ms. Sung has extensive experience guiding publicly-traded healthcare and life science companies through the initial public offering and auditing processes, having previously worked with companies based in the USA and mainland China.

Total
0
Shares
Related Posts